Periosteal hyperostosis (exostosis) was identi ed in 5.9% (11/188) of DBA/1 male mice 10-14 weeks old used for collagen-induce d arthritis (CIA) ef cacy testing of immunomodulator y biologics. Mice with and without CIA in the affected limb, and also control and treated groups, were involved, with bilateral lesions in one mouse. Hyperostosis was characterized by circumferential and raised masses of variable location, length, and laterality, generally external to but occasionally breaching the periosteum of the metatarsals, metacarpals, tibia, femur, and humerus. Proportionally, the hyperostotic foci consisted of cancellous and woven bone, followed by osteoid, cartilage, and brous connective tissue and rarely in ammatory cells. A displaced, presumably pathological fracture with callus formation was a concurrent lesion in only one case. Tartrate-resistant acid phosphatasepositive cells were frequent at bony interfaces, indicating an active resorptive process. Periosteal hyperostosi s is an incidental and potentially common nding in DBA/1 mice. Underreporting may occur due to the male bias in disease expression of this CIA model, sampling bias (generally paws only), tissue obliteration in the presence of CIA, and lack of comprehensive historical data on the backgroun d and aging lesions in this strain of mouse. Identi cation of such confoundin g bony lesions is important to the interpretation of ef cacy studies, and suggests the need to further examine the biology of bone developmen t in this strain of mouse.
INTRODUCTION
Arthritis induced by priming and challenge with autologous or heterologous collagen is a common murine model used to characterize autoimmune arthritis and to test the ef cacy of therapeutics for rheumatoid arthritis (5, 8) . Genetic susceptibility or resistance to collagen-induced arthritis (CIA) in mice is related to both major histocompatibility complex (MHC) and non-MHC genes (1, 8, 19) . Mice with the MHC class II haplotypes H-2q (DBA/1, C3H, B10.Q) and H-2r (B10.RIII, RII/SJ), H-2w3, and H-2w17 are most sensitive to induction of CIA (7) . Even within susceptible mouse strains, there is often marked heterogeneity of disease incidence and severity associated with vendor source, sexes, interexperiment and interlaboratory variability, and immunization protocols. Ability to respond to autologous collagen, T-and B-cell presence and responses, and cytokines (1, 4, 9, 10, 18, 20) also modulate susceptibility to, incidence of, and severity of CIA.
Hyperostosis or osteosclerosis (12, 21) is a nonneoplastic proliferation of woven and/or lamellar bone, cartilage, osteoid, broblasts, and giant cells that must be differentiated from osteopetrosis, osteochondrodysplasia , and broosseous dysplasia and fracture callus (3, 12, 14, 15) . Increased bone or bone-cell formation (proliferative hyperostosis) or decreased bone resorption (nonproliferative hyperostosis) may be identi ed depending on the age of the lesions. Association with preexisting bone surfaces de nes hyperostosis as periosteal (exostosis), endosteal (enostosis), and trabecular or medullary (osteosclerosis). Differentiation of hyperostosis from primary bone tumors, trauma (primary fractures), and dysplastic aging lesions may be dif cult (12) .
This report represents a case series of histologically identied periosteal hyperostosis as a confounding lesion in young male DBA/1 mice with experimental CIA used to evaluate ef cacy of novel biologics for rheumatoid arthritis.
METHODS
The data presented in this report are derived from ve separate ef cacy studies of CIA using 188 male DBA/1OlaHsd mice over a period of 3 years. Mice were obtained from Harlan UK (Blackthorn, Oxon), group housed in microisolator cages, fed rodent feed (Harland Tekland, Madison, WI) and water ad libitum, and acclimatized for 1 to 3 weeks before induction of arthritis. At 6-10 weeks of age, a standard collagen-induced arthritis protocol for mice was initiated (4) with the following modi cations. Mice were immunized with 100 l g chicken type II collagen (Sigma, Chicago) in complete Freund's adjuvant (Difco, Detroit, MI) and challenged 21 days later with 200 l g collagen in incomplete Freund's adjuvant (Difco). Within 10-14 days, the majority of the mice developed enlarged and red distal extremities indicative of CIA, and affected mice were enrolled in the treatment studies conducted using a blind code. The ef cacy treatment protocols consisted of 10-14 days of daily ip injections of control protein of 50-150 l g human immunoglobulin G (IgG; huIgG) or comparable quantities of several novel 390 0192-6233/02$3.00 $0.00 immunomodulators, at several test doses. Bony proliferation was found to be unrelated to treatment; therefore, the speci c immunomodulators, doses, and dosing regimens are not described. The nal group of four mice was collected after being excluded from a treatment study due to lack of clinically evident CIA, and all were subsequently con rmed to lack histological changes typical of CIA (negative responders).
At necropsy, only joints were sampled from mice 10-14 wk old. The skin was removed to the phalanges, and bilateral joint areas were collected by incising proximal to the appropriate joints and collecting the distal bone, muscle, and connective tissue with minimal trimming of excess muscle mass. The joint areas examined in all studies consisted of phalanges to mid-radius/ulna (forepaw), phalanges to mid-metatarsals (hindpaw), and mid-metatarsals to distal tibia/ bula (tibiotarsal/talus). The mid-radius/ulna to mid-humerus (elbow) and distal tibia/ bula to distal femur (knee) areas were also examined in four of the studies. The tissues were xed in 10% neutral buffered formalin for 24-36 h, decalci ed in formic acid or ImmunoCal (Decal Corporation, Congers, NY), embedded in paraf n, sectioned at 5-7 l m, and stained with hematoxylin and eosin (H&E) and safranin O stains. The slides were blind coded (except the last group of four mice) before evaluation and scoring for in ammatory, bony, and cartilaginous lesions. All ndings were recorded, but only typical in ammatory CIA lesions were considered further in evaluation of treatment ef cacy. Subsequently, additional sections of non-CIA proliferative lesions were step-sectioned (50-l m steps) and stained with H&E to further characterize the ndings, or stained for tartrate-resistant acid phosphatase (TRAcP) to identify osteoclastic and chondroclastic activity (kit A387, Sigma).
RESULTS
Except for a palpable mass of the left midshaft humerus in one mouse, all lesions were only identi ed histologically. As summarized in Table 1 , proliferative lesions of hard tissues were identi ed in 1.0% (12/1150) of sections examined and in 5.9% (11/164) of male DBA/1 mice. Affected mice included controls (clinical CIA and no treatment), treated mice (clinical CIA and treatment with one of several immunomodulatory molecules and doses), and those excluded from treatment (no clinical CIA and no treatment). Severe CIA obliterates normal tissue architecture; therefore, evidence of proliferation was only identi ed concurrently with minimal CIA in a single case. There was no association between location and group assignment, and no evidence of laterality, with only one animal with bilateral lesions. Lesions were identi ed equally in the paws and proximal long bones of the fore and hind limbs.
Histologically, the characteristic proliferation consisted of well-organized and focal hypertrophy of woven and lamellar bone, osteoid, and cartilage (Figure 1 ). Compared to normal cartilage, cartilage foci in lesions were generally paler by safranin O staining, indicating reduced glycosaminoglycans, and had scalloped outer margins, particularly in association with multinucleate cells, presumably chondroclasts. Clusters of broblasts, brous connective tissue, and rare in ammatory cells were present near some of the cartilaginous foci. The proliferative mass enveloped the bone beyond preexisting periosteum, with occasional and variable subperiosteal extensions. From the thickest area, the extra-periosteal hypertrophy gradually decreased proximal and distal until the lesions blended imperceptibly with the normal periosteum. The mass identi ed grossly in one case correlated with an overriding and displaced fracture of the proximal humerus with periosteal hypertrophy merging into the fracture callus ( Figure 2 ).
Step sections of the other samples did not identify any additional fractures or evidence of preexisting or concurrent lesions. In all cases, osteoblasts and osteoclasts were frequent in the regions of lamellar but not woven bone. TRAcP staining was found in both mono-and multinucleate cells in association with scalloping of the lamellar bone and cartilage (Figure 3 ).
DISCUSSION
In the mouse, differential diagnoses for spontaneous bony and cartilaginous reactions include fractures, musculoskeletal trauma, in ammation, brous-osseous dysplasia (12), idiopathic hyperostosis (12, 16) or osteosclerosis (21) , and retroviral-induced osteopetrosis (17) . Congenital proliferative lesions of bone and cartilage include diffuse spinal skeletal hyperostosis in the tiptoe-walking Yoshimura mouse (16) , osteochondrodysplasi a in mice transgenic for interferon (IFN) c (15) , and osteopetrosis in several deletional mutations (3, 11) . Pharmacologically induced alter- ations to bone may also occur in B6C3F1 mice treated with 4-hexylresorcinol, bisphosphonates , and estrogens (2, 12) .
This case series of bony and cartilaginous proliferation appeared to be most compatible with trauma or hyperostosis. The presence of hyperostosis in control mice, including those with and without proven CIA, eliminated treatment as a possible factor. Completely naive mice (i.e., those not undergoing CIA induction) were not available for examination, making it dif cult to eliminate the adjuvants or collagen used in the CIA protocol as possible factors. However, four mice (CIA 5 group) were speci cally collected to provide a sample of mice that were negative responders to collagen immunization. That a hyperostotic lesion was found in only one site in one mouse in the absence of clinically or histologically evident CIA suggests that the immunization reagents were unlikely inducers of these tissue changes. Collagen alone induces autoimmune arthritis (5) , but there are no published reports of Freund's adjuvants alone inducing any nonin ammatory changes to bone or cartilage. Typically, intradermally administered Freund's adjuvants cause exuberant and persistent granulomas and granulomatous in ammation localized to the site of injection. Extension of the in ammation and erosion of adjacent bone can be a debilitating adverse event at the classic CIA induction site at the head of the tail in mice (Schuh, unpublishe d data). While conceivable, proliferation in the absence of in ammation would be dif cult to attribute to, and uncharacteristic of the known effects of the reagents used for CIA. Other differential diagnoses were eliminated due to the predominance of proliferative bone, lack of in ammation and lysis, young age, focal nature of the ndings, and speci c-pathogen-free source colony for these animals. Although sporadic periosteal trauma or fractures cannot be fully eliminated as a cause of the proliferation, the frequency is higher than would be expected for an incidental nding. Furthermore, similar lesions were not identi ed in many other strains of mice used in our facility over this period. DBA/1 mice, particularly males, have high open-eld and locomotor activity, and accidental fractures might occur when these temperamentally hyperactive mice are forcibly removed from cage surfaces for examination. However, if fractures were the underlying cause of the proliferative lesions in this case series, lesions would be expected to occur almost exclusively in the predominate sites of the tibia and bula (12) .
Step sectioning did not reveal any underlying fractures or other causes for the proliferation. Therefore, the ndings were considered most compatible with spontaneous periosteal hyperostosis as previously described in aging B6C3F1 and ICR mice (2, 12) . Despite variations in the size and location of the hyperostosis, bone predominated over cartilage and brous connective tissue. Multinucleate and mononucleate cells were frequent ndings in association with resorptive pockets along bone and cartilage, suggesting that these lesions were formed by a proliferative (increased bone and resorption) rather than a nonproliferative (reduced bone resorption) mechanism (12) . In one case where a fracture was identi ed grossly, hyperostosis was found for a considerable distance distal to but merging with the nonunion fracture and callus formation. This suggested that the hyperostosis was concurrent with a pathological fracture. However, fracture callus is a special form of hyperostosis (6, 12) , and this case highlights the dif culty of separating cryptogenic proliferation and active reparative processes in bone.
Despite their use in numerous immunological studies and as a CIA susceptible strain, ndings of background or incidental lesions in tissues have not been described in DBA/1 mice. Testing for ef cacy of biologics often requires the use of speci c strains of mice for which there is considerable immunological but little pathophysiologica l characterization. A nearly 6% incidence of spontaneous periosteal hyperostosis in DBA/1 males suggests the need to fully evaluate the bone biology and pathology in this strain. This is supported by a recent study on genetic variability of ectopic osteoinduction in inbred and outbred mice (13) . Differences in bone mass and morphology after an osteoinductive implant were not associated with MHC haplotype, expression of bone morphogenic proteins, or spontaneous physical activity. High responders that produced bone, cartilage, and bone marrow were independently derived strains such as the DBA/2, RFM, C57BL/6, and ADR mice. Poor responders, de ned by predominate cartilage production, included mice with common derivation from Bagg albino stock (BALB/c, A, CBA, and C3H). Genetically based hyperactive osteoinduction after periosteal trauma may be the basis for hyperostosis in DBA/1 mice.
The true incidence of spontaneous hyperostosis previously described in aging B6C3F1 and ICR mice (12, 21) and in our DBA/1 mice remains unknown. Incidental bone abnormalities are dif cult to document in mice due to the lack of gross ndings to aid identi cation of affected tissues. Due to the nature of CIA studies with DBA/1 mice, males are almost exclusively used, and sampling artifact occurs as most investigators only evaluate the paws for correlation to clinical scores. The true incidence of hyperostosis in DBA/1 mice could only be determined by evaluation of the entire skeleton in males and females. In ammatory models such as CIA in DBA/1 mice are also incompatible with proper evaluation of spontaneous bony changes due to the destructive nature of CIA that obscures incidental ndings except in unaffected or minimally in amed joint areas. Irrespective of the true incidence, recognition of periosteal hyperostosis as a confounding lesion in DBA/1 mice with CIA is important to interpretation of ef cacy studies used for biologics intended as modulators of rheumatoid arthritis. Additional evaluation of DBA/1 mice may also aid in the characterization of genetic differences in bone biology.
